(SVRI) and pulmonary vascular resistance index (PVRI) (n = 41) were randomly allocated into control (n = 20) and terlipressin groups (n = 21). Terlipressin was infused at 1.0 -4.0 µg/kg per h in the terlipressin group during surgery. Controls received generally accepted inotropic and vasopressor agents. RESULTS: Terlipressin infusion induced significantly higher SVRI and PVRI at 60 min after drug infusion, produced significantly greater hourly urine output during the anhepatic phase, and was related to significantly shorter stays in the postoperative intensive care unit (ICU) compared with control treatment (mean ± SD ICU stay 5.7 ± 1.5 versus 6.9 ± 1.5 days, respectively). Patients given a terlipressin infusion > 2.0 µg/kg per h during the preanhepatic phase had a median ICU stay of < 6 days (sensitivity 90.0%; specificity 89.0%). CONCLUSIONS: Terlipressin infusion improved low SVRI and PVRI during LDLT and may have contributed to better renal function and shorter ICU stays.
Introduction
Liver transplantation is usually accompanied by marked haemodynamic instability caused by preoperative medical conditions as well as surgical interventions. Impaired hepatic clearance often causes the levels of endogenous vasodilators in patients with endstage liver disease to increase. 1 This results in a decline in systemic vascular resistance (SVR) and redistribution of body fluid from the central to the peripheral compartment, reducing effective blood flow to the organs. 1 Complications such as infection, bleeding, ascites and renal dysfunction are closely related to these haemodynamic perturbations. 2 Surgical processes play important roles in generating cardiovascular instability during liver transplantation. Wide dissection of portosystemic collateral vessels and an inherent haemorrhagic tendency frequently result in life-threatening blood loss. Clamping or unclamping of great vessels can also produce marked shifts in body fluid and cause ischaemia-reperfusion injury in many organs.
Rational fluid and vasopressor administration are crucial to control SH Hong, JM Lee, JH Choi et al. Terlipressin infusion during liver transplantation haemodynamic instability during surgery. Despite controversy, 3 the use of vasoconstrictors during liver transplantation has been advocated because of their many beneficial effects on perioperative outcome. 2 Under conditions of hepatic cirrhosis, the vasoconstrictors return hepatosplanchnic blood to the central compartment, improving perfusion into major organs, including the kidneys. 4 -7 Vasoconstrictors also decrease portal vein pressure and flow to the cirrhotic liver without decreasing cardiac output, 8 which may reduce blood loss and transfusion volume during liver transplantation. In addition, the use of vasoconstrictors together with restricted fluid administration can improve postoperative pulmonary outcome. 9 Terlipressin (triglycyl-lysine vasopressin), a long-acting synthetic analogue of arginine vasopressin, has been used in the treatment of paracentesis-induced circulatory dysfunction with tense ascites as well as hepatorenal syndrome and variceal bleeding in patients with end-stage liver disease. 10 Although there have been relatively few studies of plasma concentrations after bolus injection, bolus injection of 0.5 -1.0 mg terlipressin is clinically preferred because of the long-lasting effect of the drug. It has been suggested that bolus injection may cause sustained global or regional vasoconstriction, 11 possibly compromising the patency of reconstructed small-sized vessels during living donor liver transplantation (LDLT). On the other hand, continuous infusion of low-dose terlipressin has been shown to be effective in reversing sepsis-induced arterial hypotension when given as a first-line vasopressor agent. 12 Based on these observations, titrated terlipressin infusion was suggested to have a beneficial effect on haemodynamics and related perioperative outcomes in LDLT. 10 -13 The aim of the present prospective, randomized, controlled study was to investigate the safety and efficacy of intraoperative infusion of terlipressin in comparison with conventional vasopressors in patients undergoing LDLT. 
Patients and methods

STUDY POPULATION SELECTION AND ALLOCATION
SURGICAL PROCEDURES
The same two surgeons performed right lobe LDLT using the piggyback technique in all cases. During dissection of the recipient's liver, bleeding was controlled with haemostatic clips or hand ties. In all cases, portal vein anastomosis was followed by hepatic artery anastomosis and bile duct reconstruction. Neither venovenous bypass nor temporary portocaval shunt was used.
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INTRAOPERATIVE MANAGEMENT AND DRUG INFUSION
The anaesthetic technique (thiopental sodium, atracurium, isoflurane) was standardized for all patients. A 22-gauge angiocatheter was inserted into the right radial artery for continuous blood pressure monitoring and arterial blood gas analysis. A 9 Fr multilumen introducer (MAC™; Arrow International, Reading, PA, USA) was passed through the right internal jugular vein and attached to a rapid infusion system (FMS2000; Belmont Instrument Corp., Billerica, MA, USA) for rapid infusion of blood and fluid. A Swan-Ganz catheter (Arrow International) was inserted via the introducer and used to monitor and measure haemodynamic variables. The right subclavian vein was catheterized with a twolumen catheter (Arrow International) and used as a channel for administration of drugs.
Crystalloid solutions were infused as maintenance fluid, with the infusion rate adjusted to maintain central venous pressure (CVP) > 5 mmHg. Loss of albumin related to ascites was supplemented with 20% albumin solution. Packed red blood cell transfusion was performed with a target haematocrit of 30%, and fresh frozen plasma, platelet concentrate and cryoprecipitate were administered under the guidance of thromboelastography or coagulation profile such as platelet count, prothrombin time or activated partial thromboplastin time. Tranexamic acid was administered when excessive fibrinolysis was indicated by thromboelastography.
During surgery, either inotropes or vasopressors were infused to maintain haemodynamic stability. Patients in the control group received conventionally accepted inotropic agents, such as dopamine and/or dobutamine, when mean arterial pressure (MAP) was < 65 mmHg despite adequate volume resuscitation. Patients with hypotension unresponsive to moderate doses (5 -8 µg/kg per min) of inotropic agents received supplementation with vasopressors such as noradrenaline or adrenaline, as appropriate, in the form of a bolus injection. Terlipressin at a dose of 1.0 -4.0 µg/kg per h was continuously infused into the patients in the terlipressin group. Terlipressin infusion started at a dose of 1.0 µg/kg per h, with the rate titrated to maintain a MAP > 65 mmHg and SVRI < 2600 dyne·s/cm 5 per m 2 . To minimize the effects on blood flow to the graft liver, the infusion of vasopressors, including terlipressin, was limited until 60 min after reperfusion of portal vein flow. 16 
MEASUREMENTS AND INTRAOPERATIVE DATA COLLECTION
Haemodynamic variables included MAP, heart rate, CVP, cardiac index, SVRI and PVRI. Cardiac output was measured by the thermodilution method using the Swan-Ganz catheter. The other haemodynamic variables were measured with a patient monitor (IntelliVue MP70; Philips Medical Systems, Böblingen, Germany) or were calculated using standard formulae. To evaluate global tissue oxygenation, arterial and mixed venous blood samples were taken and analysed with a blood gas analyser (ABL800 FLEX; Radiometer, Brønshøj, Denmark). Differences between arterial and venous oxygen content and the oxygen extraction ratio were calculated from the standard formula. Acid-base balance variables included arterial pH and lactate, which were determined by arterial blood gas analysis. Other variables measured were the amount of bleeding, fluid requirement, transfusion volume and hourly urine output.
Data were collected at the following times: T 1 , immediately after anaesthetic preparation; T 2 , 60 min after commencement of SH Hong, JM Lee, JH Choi et al.
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terlipressin infusion, or 60 min after T 1 in control patients; T 3 , 120 min after commencement of terlipressin infusion, or 120 min after T 1 in control patients; T 4 , 30 min after clamping of the portal vein; T 5 , 10 min after reperfusion of the portal vein; and T 6 , 60 min after reperfusion of the portal vein. These time points were further classified as preanhepatic (T 1 , T 2 , T 3 ), anhepatic (T 4 ) and neohepatic (T 5 , T 6 ).
POSTOPERATIVE OUTCOMES
Immediate postoperative outcomes were followed up until day 10 after surgery. Death, intensive care unit (ICU) stay, graft rejection or dysfunction, bleeding, vascular thrombosis, cardiovascular events, hypotensive episodes, renal dysfunction and infection were included in the postoperative outcomes by application of respective clinically accepted definitions.
STATISTICAL ANALYSES
According to preliminary observations, the mean ± SD SVRI at 60 min after terlipressin infusion was estimated to be 1472 ± 284 dyne·s/cm 5 per m 2 and to be 20% increased compared with the control group. Using a power of 0.8 and α = 0.05, a minimum sample size of 16 patients was calculated for each group. A total of at least 19 patients were required in each group to compensate for possible dropouts. Repeated measures analysis of variance was used for intergroup comparison of haemodynamics, global tissue oxygenation and acid-base balance data, which were obtained at consecutive time points. Intergroup differences in other continuous variables were analysed with the unpaired t-test or Mann-Whitney U-test and categorical variables were compared using the χ 2 -test. Correlations of terlipressin infusion rates with perioperative variables were analysed using Pearson's correlation coefficient. The sensitivity and unbiased estimate of the predictive function of intraoperative terlipressin infusion for postoperative outcomes were evaluated from the area under the receiver operating characteristic curve (AUC). Values are expressed as mean ± SD, median (interquartile range), or absolute numbers (percentage). Statistical analyses were performed using SPSS ® version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value of < 0.05 was considered to be statistically significant.
Results
Of the 93 patients who underwent liver transplantation during the study period, a total of 52 were excluded: 20 patients were disqualified according to the exclusion criteria (18 patients with SVRI ≥ 1700 dyne·s/cm 5 per m 2 and two patients with severe haemodynamic instability); and 32 patients refused to participate. A total of 41 patients were randomly allocated into the two groups (control group, n = 20; terlipressin group, n = 21) and were included in the analyses. The baseline demographic and clinical characteristics of the included patients are summarized in Table 1 . There were no statistically significant differences between the two groups in terms of gender, age, body weight, CTP classification, 14 MELD score, 15 or indications for LDLT. The amounts of terlipressin infused in the terlipressin group at the different time points during LDLT were (mean ± SD): T 1 At T 2 , the SVRI and PVRI were significantly higher in the terlipressin group than in the control group (mean ± SD SVRI 1578.1 ± 533.5 versus 1114.2 ± 441.0 dyne·s/cm 5 per m 2 , P = 0.007; mean ± SD PVRI 128.8 ± 76.0 versus 86.5 ± 31.7 dyne·s/cm 5 per m 2 , P = 0.032; Fig. 1 ); SVRI showed a significant interaction in the two groups over time (F = 2.629; P = 0.046). There were no other statistically significant between-group differences in haemo dynamics, global tissue oxygenation and acid-base balance variables at any other time point ( Fig. 1 ).
There were no significant differences in estimated blood loss, fluid requirements, or transfusions between the two groups ( Table  2 ). Overall (mean) hourly urine outputs did not differ between the two groups, but hourly urine output was significantly higher in the terlipressin group than in the control group during the anhepatic stage (P = 0.004). It was necessary to increase the mean dosage of terlipressin infusion for haemodynamic support with progression of the surgical phase (preanhepatic phase 2.51 ± 1.08 µg/kg per h; anhepatic phase 2.66 ± 1.29 µg/kg per h; neohepatic phase 2.74 ± 1.99 µg/kg per h). The infusion rate of terlipressin was inversely correlated with hourly urine output after reperfusion of portal vein flow (r = -0.532 at T 5 , r = -0.578 at T 6 ; P < 0.05 for both).
The ICU stay was significantly longer in the control group than in the terlipressin group (P < 0.05), whereas postoperative duration of intubation was not significantly different between the two groups ( Table 3 ). The infusion dose of terlipressin at T 2 (mean ± SD dose 2.50 ± 0.95 µg/kg per h) was inversely correlated with length of ICU stay (r = -0.559;
Control group
Terlipressin group Characteristics n = 20 n = 21 Comparison of the postoperative complications between the two groups is shown in Table 3 . There was no significant difference in the total number of patients who died or experienced complications during the immediate postoperative period.
Hepatic artery stenosis occurred in one patient in the control group and a stent was inserted. There were no intergroup differences in the incidence of severe cardiovascular events or infection at any site (surgical site, lung, urine, or blood). Although renal dysfunction requiring dialysis occurred in one patient in the control group, peak serum creatinine levels until postoperative day 10 were similar in both groups. PVRI, pulmonary vascular resistance index; O 2 ER, oxygen extraction ratio; PaO 2 , arterial oxygen tension; T 1 , immediately after anaesthetic preparation; T 2 , 60 min after commencement of terlipressin infusion or 60 min after T 1 in control patients; T 3 , 120 min after commencement of terlipressin infusion or 120 min after T 1 in control patients; T 4 , 30 min after clamping of the portal vein; T 5 , 10 min after reperfusion of the portal vein; T 6 , 60 min after reperfusion of the portal vein; *P = 0.032, **P = 0.007 compared with the control group, unpaired t-test) 
SH Hong, JM Lee, JH Choi et al. Terlipressin infusion during liver transplantation
preanhepatic phase and resulted in better urinary function during the anhepatic phase. Post-transplant complications such as graft dysfunction, bleeding, thrombotic episodes in the hepatic artery or portal vein, immunosuppressant-related complications, infection and renal dysfunction are common causes of prolonged ICU stay after LDLT. 17 Although many confounding factors were not taken into consideration, intraoperative terlipressin infusion also contributed to a significantly shorter postoperative ICU stay. The incidence of postoperative complications, including renal dysfunction, in patients given intraoperative terlipressin infusion was not significantly different from the control patients treated with conventional vasopressors. Terlipressin infusion was not sufficiently effective to decrease intra operative bleeding (transfusion requirements) or the volume of fluid required.
Traditionally, terlipressin has been administered by intermittent intravenous bolus injection, rather than by continuous infusion. Recent studies have suggested that terlipressin may also be administered as a lowdose continuous infusion (1.3 -2.6 µg/kg per h) in the early course of distributive shock. 18, 19 This approach sufficiently increased systemic blood pressure without unwanted side-effects, such as an exaggerated increase in peripheral resistance. 18, 19 The doses used in the present study were similar to the range of doses previously used for low-dose infusion. 18, 19 The vascular resistance of liver transplantation patients deteriorates with time of surgery, reaching its lowest level just after reperfusion of portal flow, owing to a massive influx of vasodilators from the vascular endothelium of the liver graft. 20 In the present study, infused terlipressin doses had to be increased incrementally with LDLT phases, and proper titration was required to compensate for the decline of vascular resistance and to maintain vital signs within safe ranges.
Normalizing SVR in cirrhotic patients with portal hypertension has several benefits. In these patients, expansion in central blood volume is not sustained and is rapidly redistributed to the hepatosplanchnic circulation. 21 The elevated SVR returns hepatosplanchnic blood to the central compartment, improving perfusion into major organs and maintaining systemic blood pressure. 2 Compromised cardiac output during clamping of the inferior vena cava must be supported by increased SVR without venovenous bypass, since excessive compensation by fluid augmentation may cause right heart dysfunction after reperfusion of portal venous flow. 22 Although bolus injection of terlipressin may reduce cardiac function, 23 infusion in the present study did not have harmful effects on cardiac indices. In addition, peripheral vasoconstriction by terlipressin infusion was not so severe that it aggravated global tissue hypoperfusion, as shown by the lack of progress of metabolic acidosis and arteriovenous difference in oxygen content.
Many previous studies have shown terlipressin to be effective in cirrhotic patients with type 1 hepatorenal syndrome (HRS). 24 Although not all patients undergoing liver transplantation have symptoms and signs of HRS, it is reasonable to assume that most have the pathophysiological potential to develop renal dysfunction due to cirrhotic liver failure. Intraoperative blood loss or body fluid shift during the surgical processes may also increase the risk of developing renal dysfunction. In a previous clinical study, noradrenaline plus dopamine infusion during orthotopic liver transplantation increased overall urine output compared with infusion of dopamine alone. 7 The renal vascular dilatory effect of noradrenaline was thought to be related to the increase in SH Hong, JM Lee, JH Choi et al.
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systemic blood pressure which, in turn, triggered a pressure response to decrease renal sympathetic nerve tension. In addition to this mechanism, terlipressin administration can improve renal function by decreasing plasma concentrations of renin and aldosterone 25 which, in turn, ameliorates renal artery constriction. The favourable perioperative renal function effects of the vasoconstrictors used in liver transplantation seem to require support by adequate fluid administration. In a retrospective record review, a low CVP strategy with the support of vasoconstrictors resulted in significantly higher incidences of postoperative renal dialysis and 30-day mortality compared with a normal CVP strategy. 3 In the present study, a favourable volume status was maintained for the patients in the terlipressin group, manifested by similar CVP levels in both groups throughout surgery.
The higher urine output during the anhepatic phase in the terlipressin group compared with the control group seems to be related to the surgical process. Clamping of the portal vein and inferior vena cava causes vasoconstriction of the renal arteries, which was more severe in the control group than in the terlipressin group. Since the use of vasoconstrictors was reduced as far as possible in the present study, SVRI in the control group increased more prominently during the anhepatic phase. The lack of a difference in urine output between the groups during the other LDLT phases also indirectly implies safety with a low incidence of complications for terlipressin infusion. In addition, intact postoperative renal function in the terlipressin group indicated safety of terlipressin infusion during surgery. It was necessary carefully to titrate the infusion dose of terlipressin, however, especially after reperfusion to the portal vein, because of its possible negative effect on urine output.
Vasopressor administration during liver transplantation may have beneficial effects on postoperative fluid shift and on resulting pulmonary complications such as pulmonary oedema. In a study of orthotopic liver transplantation, the use of noradrenaline as an adjuvant, together with controlled fluid administration, to maintain a stable haemodynamic status reduced the need for endotracheal reintubation compared with placebo. 9 Generally, the endocrine response to surgical trauma leads to conservation of sodium and water and excretion of potassium, the principal mediators being antidiuretic hormone, aldosterone and the renin-angiotensin II system. 26 It is, therefore, postulated that vasopressor administration may affect secretion of these mediators. Further studies are required to confirm this hypothesis.
It should be noted that there were no differences between the groups in terms of administration of fluids or blood products. In addition, the patients in the terlipressin group tended to have more severe medical conditions preoperatively than those in the control group, manifested by the slightly higher incidence of CTP class C and slightly higher MELD scores, although these differences were not statistically significant. The ICU stay was significantly shorter in the terlipressin group than in the control group and was thought to be attributable to the slightly shorter postoperative duration of intubation, although the difference was not statistically significant. The present study indicated the importance of early administration of terlipressin during the preanhepatic phase with concentrated surgical dissection and bleeding, and suggested more aggressive increases in the dosage of terlipressin infusion (> 2 µg/kg per h) might result in a shorter postoperative ICU stay.
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portal vein pressure and flow in the native liver without decreasing cardiac output or intestinal perfusion in patients undergoing liver transplantation. 8 Reduction of portal vein pressure and flow during and after liver transplantation has several potential benefits. Although not effective in this study, reduced portal vein pressure and flow are expected to decrease the amount of intraoperative bleeding and transfusion. 27 The absence of this benefit in the present study might have been due either to the infused terlipressin doses being inadequate to lower portal pressure and flow, or to the onset of terlipressin action being too slow to reduce bleeding during the preanhepatic phase, when most intraoperative bleeding occurs. Surgical factors, such as bleeding associated with wide dissection of portosystemic collateral vessels, may also compromise the benefit of reduced portal pressure and flow.
Reduced portal pressure and flow has another potential benefit, especially in LDLT. Early postoperative elevation of portal vein pressure to ≥ 20 mmHg has been shown to be associated with rapid graft hypertrophy and graft dysfunction. 28 Adequate liver regeneration requires adequate increases in portal vein pressure and flow. Infusion of vasopressin or vasopressin analogues after reperfusion of the portal vein would be helpful in adjusting portal pressure and flow, especially in small-for-size grafts. In the present study, however, the infusion of terlipressin was limited until 60 min after reperfusion of portal vein flow for fear of reducing blood flow to the grafted liver.
The present study had several limitations. First, the study was not performed in a double-blind manner, so further trials that are double-blinded are required. Secondly, the relationships between portal vein pressure and perioperative variables could not be analysed because of failure to establish a catheter for measurement of portal vein pressure. Thirdly, the dose of terlipressin should have been titrated more aggressively to reduce blood or fluid administration. Nevertheless, the present study is significant in that it demonstrates the beneficial effects of low-dose terlipressin infusion on intraoperative renal function and shortening of ICU stay after LDLT.
In conclusion, intraoperative infusion of terlipressin was shown to be an effective technique for elevating low SVRI in patients undergoing LDLT, possibly improving renal function and reducing postoperative ICU stay. Further investigations are required to determine more accurately the optimal dose of terlipressin for improved perioperative outcome.
